Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.11.18 (
MAP
)
7,412
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Molybdenum trioxide
(MoO
3
) nanoparticles (NPs) embedded in polymer films have been proposed as a cheap way of producing antibacterial coatings on external surfaces. Recently, we synthesized MoO
3
nanowires in a unique shape and degree of anisotropy, which enables their fast water dissolution and quick antimicrobial reaction. Potential human health risks following the exposure to MoO
3
NPs however need to be assessed prior their wide use. We therefore, investigated the biological effect of these newly synthesized MoO
3
NPs on the human keratinocyte cell line HaCaT, used here as a model for the human skin. Exposure of HaCaT cells to 1 mg/mL MoO
3
NPs concentration for 1 h showed no effect on cell survival, had no influence on reactive oxygen species production, expression of proteins involved in antioxidant defense, secretion of pro-inflammatory cytokines, nor induced DNA damage. Interestingly however, ERK and p38
MAP
kinases were activated, and upon longer time exposure, induced a moderate release of the pro-inflammatory cytokine interleukin 6, increased DNA damage and increased the level of caspase independent cell death. Our study indicates that exposing HaCaT cells to antibacterial MoO
3
NPs water-based solution in durations less than 1 h exhibits no cytotoxicity, but rather triggers cell signalling involved in cell survival and inflammation; which should be taken into consideration when evaluating MoO
3
NPs for medical applications.
...
PMID:In-vitro toxicity of molybdenum trioxide nanoparticles on human keratinocytes. 3289 20
